Geode Capital Management LLC Purchases 11,689 Shares of Natera, Inc. $NTRA

Geode Capital Management LLC grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 0.5% in the 4th quarter, HoldingsChannel reports. The firm owned 2,608,644 shares of the medical research company’s stock after acquiring an additional 11,689 shares during the quarter. Geode Capital Management LLC’s holdings in Natera were worth $596,078,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the company. Horizon Investments LLC increased its holdings in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares during the last quarter. Sound Income Strategies LLC grew its holdings in Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares in the last quarter. Savvy Advisors Inc. grew its holdings in shares of Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after purchasing an additional 46 shares in the last quarter. Siemens Fonds Invest GmbH lifted its position in Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after buying an additional 54 shares during the last quarter. Finally, First Horizon Corp lifted its position in Natera by 7.3% in the 4th quarter. First Horizon Corp now owns 931 shares of the medical research company’s stock worth $213,000 after buying an additional 63 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Natera Stock Performance

Shares of Natera stock opened at $223.37 on Friday. The stock has a market cap of $31.99 billion, a price-to-earnings ratio of -137.04 and a beta of 1.57. The stock has a 50 day moving average price of $202.37 and a 200-day moving average price of $215.69. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter in the previous year, the business earned ($0.41) EPS. Sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Natera news, CFO Michael Burkes Brophy sold 3,070 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total transaction of $594,781.80. Following the sale, the chief financial officer owned 58,291 shares in the company, valued at approximately $11,293,298.34. The trade was a 5.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 5,838 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $204.14, for a total value of $1,191,769.32. Following the completion of the transaction, the chief executive officer directly owned 150,769 shares of the company’s stock, valued at $30,777,983.66. The trade was a 3.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 41,356 shares of company stock valued at $8,374,584. 5.63% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on NTRA shares. Wells Fargo & Company increased their price objective on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. William Blair initiated coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Evercore reaffirmed an “outperform” rating and set a $270.00 price objective on shares of Natera in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $256.60.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.